Oncolytics Biotech Inc. (ONCY) Stock Score, Valuation & Financial Research
Oncolytics Biotech Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.
Quick answer for ONCY
Oncolytics Biotech Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.49. These figures are a research snapshot, not a buy or sell recommendation.
What Oncolytics Biotech Inc. does
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Company business and revenue
Research reporting period: 2025-12-31. A research update is not a new financial filing.
How the company makes money
Oncolytics Biotech is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on financing operations through public or private equity or debt financings, with the long-term goal of generating revenue through future product licensing or commercial sales of its therapeutic candidates.
Products and services
- The company is developing pelareorep, an intravenously delivered immuno-oncolytic virus (IOV) designed to induce selective tumor lysis and activate the innate and adaptive immune systems to treat various solid tumors.
Brands and product families
- pelareorep — The company's lead investigational immuno-oncolytic virus product candidate. Source
Customer types
Clinical research organizations and medical institutions.
Suppliers, materials and equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials; specific supplier names are not disclosed. Source
Business strengths to evaluate
- Proprietary immuno-oncolytic virus platform (pelareorep) Source
Business risks and research considerations
- History of operating losses and expectation of future losses Source
- Dependence on additional capital to fund clinical development Source
- Risks associated with clinical trial success and regulatory approval Source
Sources: Company research source
Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.
ONCY financial snapshot
Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.
- Wall Street Score:
- Not currently available
- Stored price:
- USD 0.49
- Market capitalization:
- 49.49M (currency not supplied)
- Revenue:
- USD 0.00
- Net income:
- USD -26.8M
- Free cash flow:
- USD -14.11M
- Cash:
- USD 2.89M
- Total debt:
- USD 314.24K
- EPS:
- USD -0.24
What stands out
- Free cash flow is USD -14.11M, negative for the stored period.
- The balance sheet shows USD 2.89M of cash versus USD 314.24K of total debt, an excess of cash over debt on these two reported measures.
- The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.
Company-specific financial comparisons
The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.
- Cash exceeds debt by USD 2.57M using the stored balance-sheet values. This does not include other obligations or restricted cash.
Questions worth answering for ONCY
Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.
- How long can ONCY fund negative free cash flow using its current cash position before it may need more debt or new shares?
- How is ONCY likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- What specifically needs to improve for ONCY to reach sustainable profitability?
- What does the current fundamental change risk warning mean for the reliability or interpretation of ONCY's score?
What the numbers mean
A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.
A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-10-12.
Research-input completeness: 64% of the scoring inputs required for this public page are currently available.
How to research ONCY
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.